The Veterinary Medicines Directorate reported on 1 September 2026 that the Summary of Product Characteristics (SPC) for Solensia 7 mg/ml Solution for Injection for Cats had been updated following monitoring of pharmacovigilance data. The SPC now states that ataxia, polyuria and polydipsia can occur very rarely, defined as fewer than 1 animal per 10,000 treated, including isolated reports, after administration of the product.

The VMD said updated SPCs supply label text and are listed on its Product Information Database almost immediately once approved, but that changes may take up to 12 months to appear on marketed packaging. It added that adverse events are listed in SPC sections 3.6 or 4.6, and that SPC updates other than template changes appear in the medicine updates section of VMD Connect.

The agency encouraged anyone aware of an adverse event to report it once, including the batch number, either to the Marketing Authorisation Holder or to the VMD, noting that duplicate reports can affect data handling. It described adverse-event reporting as critical to its monitoring work.